A Extension Study to Evaluate Revusiran (ALN-TTRSC) in Patients With Transthyretin (TTR) Cardiac Amyloidosis
Clinical trial NCT02292186 · COMPLETED
Trial details
- NCT number
- NCT02292186
- Sponsor
- Alnylam Pharmaceuticals
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2014-10-01
- Primary completion
- 2017-02-22
- Enrollment
- 25
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.